These symptoms could indicate a range of conditions, including liver inflammation, bile duct obstruction, or gallbladder disease (such as cholecystitis or cholelithiasis, which can occur with rapid weight loss and are known risks with GLP-1 receptor agonists)
This was achieved through careful selection of amino acid residues, particularly in the N-terminal region centered around the unmodified His1, and through optimization of the mid-chain and C-terminal regions to simultaneously support binding at all three receptors
This includes checking for problems like obstructive sleep apnea or gallbladder disease
However, hunger will not completely disappear
doi: 10.1186/1471-2202-13-33 145 GaberySSalinasCGPaulsenSJAhnfelt-RnneJAlanentaloTBaqueroAFet al
Gradual dose escalation is used to minimise gastrointestinal side effects such as nausea, vomiting, and diarrhoea, which are most common at higher doses